AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02798900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional task-training
Description: The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
Study NCT02798900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional task-training
Description: The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
Study NCT02798900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Ultrasound
Description: Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
Study NCT01808352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FTC/TDF
Description: All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
Study NCT00278135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA (nutritional supplement) or placebo
Description: oral 900mg/day
Study NCT00278135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHA (nutritional supplement) or placebo
Description: oral 900mg/day
Study NCT04233905 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychometric questionnaire study
Description: Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
Study NCT00918333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given PO
Study NCT00918333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT00918333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00918333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03135782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Undergo motivational interviewing training
Study NCT03135782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Undergo medical chart review
Study NCT03135782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03135782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Attend phone or in-person motivational interviewing coaching sessions
Study NCT00797056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 5 mcg/kg/day SQ daily for 10 days
Study NCT00797056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline SQ daily for 10 days
Study NCT00797056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 75 mg/day for 14 days
Study NCT00797056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 75 mg/day for 14 days
Study NCT00797056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg/day daily for 14 days
Study NCT00797056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg/day daily for 14 days
Study NCT05329519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening music
Description: Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
Study NCT03267537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine CBT-I
Description: Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
Study NCT03267537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional office-based CBT-I
Description: Conventional office-based CBT-I
Study NCT03620955 — intervention group
Intervention type: OTHER
Intervention: Justified risk stratification based on MRD after three course chemo therapy
Description: All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
Study NCT00273052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Phosphate modified release formulation
Study NCT00273052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate
Study NCT01267643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly
Study NCT03941106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated repetitive transcranial magnetic stimulation
Description: Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
Study NCT05038215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence promotion techniques
Description: The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
Study NCT05038215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: The control group will receive routine care
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90mg/m\^2 d1 iv Q2W for 4 cycles
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m\^2 d1 iv Q2W for 4 cycles
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 d1 iv Q2W for 4 cycles
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 d1 iv Q2W for 4 cycles
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxanes
Description: Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
Study NCT04290793 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
Study NCT04290793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
Study NCT01438801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin [Somatropin (rDNA origin) for injection]
Description: Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
Study NCT01371253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo wii balance training
Study NCT01371253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EVA-soles
Study NCT00405964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg Desloratadine
Description: 5-mg Desloratadine tablet, once daily for 12 weeks
Study NCT00405964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet, once daily for 12 weeks
Study NCT00812201 — intervention group
Intervention type: DEVICE
Intervention: No intervention is used. Collection of signals only.
Description: Device received per standard of care.
Study NCT03162510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
Study NCT03162510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel /nab-Paclitaxel
Description: 150 mg/m2 IVD 30 min bi-weekly.
Study NCT03162510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
Study NCT03162510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
Study NCT05282576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NPF Group
Description: Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
Study NCT05282576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
Study NCT02662153 — intervention group
Intervention type: OTHER
Intervention: Observation only
Description: No intervention.
Study NCT00944814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS with zinc
Description: Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
Study NCT00944814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LNS without zinc
Description: LNS containing no zinc
Study NCT04376684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab
Description: Otilimab will be administered once via IV route.
Study NCT04376684 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
Study NCT04376684 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
Study NCT04376684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: All participants will receive standard of care as per institutional protocol.
Study NCT04376684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: All participants will receive standard of care as per institutional protocol.
Study NCT02784119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary porto-caval shunt
Description: temporary porto-caval shunt
Study NCT03835494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
Description: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
Study NCT01797601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: 160 U of insulin
Study NCT01797601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Insulin dilution medium without insulin
Study NCT00064844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy for alcohol and smoking cessation
Description: Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
Study NCT00064844 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavior Therapy for alcohol and smoking cessation
Description: Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
Study NCT02232386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
Study NCT02232386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
Study NCT00064844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ nicotine patch
Description: Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
Study NCT00064844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicoderm CQ nicotine patch
Description: Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
Study NCT03928210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
Study NCT02520297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: Drug
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Undergo brachytherapy
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy
Study NCT02466971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT02466971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02466971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02466971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo conventional RT
Study NCT02466971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo conventional RT
Study NCT02466971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given IV
Study NCT00991419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AZD4694
Description: \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
Study NCT04229927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPDO-1603
Description: Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Study NCT03887455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
Study NCT03887455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biweekly (once every 2 weeks) administered as i.v. infusion.
Study NCT03887455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 720 milligram (mg) weekly administered as subcutaneous injection.
Study NCT03887455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 360 mg weekly administered as subcutaneous injection.
Study NCT06403306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Sulfate (Viskostat; Ultradent, Utah, USA)
Description: Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
Study NCT06403306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)
Description: Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).